Selexis Working with ImmuNext to Advance Potential Treatment for IBD

Selexis Working with ImmuNext to Advance Potential Treatment for IBD

Selexis and ImmuNext have recently inked a license agreement, giving ImmuNext access to research cell banks from Selexis’ SURE technology Platform. Under the terms of the agreement, ImmuNext will use Selexis cell banks to further develop its anti-CD40 ligand antibody, a potential treatment for chronic autoimmune diseases, including inflammatory bowel disease (IBD).

Mammalian cell culture technology is usually used as a production platform for monoclonal antibodies (mAbs), the fastest growing area of the biopharmaceutical industry, which can be applied to a wide range of diseases.

Selexis’ SURE CHO-M Cell Line technology incorporates a stable and high performance manufacturing mammalian cell line (suspension-adapted CHO-K1), the company said in a press release. Its SURE technology Platform improves the way mammalian cells are used, enabling a rapid, stable, and cost-effective manufacturing of recombinant proteins, supporting the development of biologic therapeutic agents from their discovery through commercialization.

CD40 ligand (CD40L)  is a protein that belongs to the tumor necrosis factor receptor (TNFR) superfamily. CD40L is expressed on the surface of a variety of immune and non-immune cell types, including B cells, macrophages, dendritic cells (DCs), and microglia. Given its central role as a key regulator and amplifier of immune reactivity, CD40L significantly contributes to the development and progression of multiple autoimmune diseases, such as IBD.

“We are pleased to expand our relationship with ImmuNext, which began out of a necessity to rapidly and predictably develop a high productivity cell line that would meet ImmuNext’s demand projections in the event of a successful clinical development and commercial launch of their anti-CD40L antibody,” Yemi Onakunle, PhD, vice president, licensing and business development at Selexis, said in a recent press release.

“ImmuNext’s development program received a $1.8M Small Business Innovation and Research (SBIR) Phase 2B award from the National Institutes of Health earlier this year for pre-clinical development of its proprietary anti-CD40L antibody. The Selexis team is proud to have played a small role in helping the company to advance its research and secure such an important award that will help to meet unmet medical need,” Onakunle added.